| Schedule of Reconciliation of Condensed Consolidated Operating Expenses and Loss |
A reconciliation to condensed consolidated operating expenses as our single segment operating loss for the three months ended March 31, 2026 and 2025, is included in the table below:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2026 |
|
|
2025 |
|
Direct research and development expenses |
|
|
|
|
|
|
Research and development salaries and benefits |
|
$ |
3,769,049 |
|
|
$ |
2,651,894 |
|
Clinical trial expense |
|
|
3,196,835 |
|
|
|
1,927,208 |
|
Lab supplies and animal care |
|
|
1,094,645 |
|
|
|
556,421 |
|
Lab services, consulting, and other direct research costs |
|
|
1,002,618 |
|
|
|
942,704 |
|
Total direct research and development expenses |
|
|
9,063,147 |
|
|
|
6,078,227 |
|
Indirect research and development expenses |
|
|
1,472,920 |
|
|
|
1,246,805 |
|
Share based compensation (research and development) |
|
|
2,861,910 |
|
|
|
332,289 |
|
Total research and development expense |
|
|
13,397,977 |
|
|
|
7,657,321 |
|
General and administrative expense |
|
|
|
|
|
|
Administrative payroll |
|
|
1,818,302 |
|
|
|
1,352,628 |
|
Professional fees and travel |
|
|
717,451 |
|
|
|
425,638 |
|
Insurance, office expense, and other administrative expenses |
|
|
1,466,004 |
|
|
|
1,055,853 |
|
Share based compensation (general and administrative) |
|
|
2,598,002 |
|
|
|
280,662 |
|
Total general and administrative expenses |
|
|
6,599,759 |
|
|
|
3,114,781 |
|
Total operating expense |
|
$ |
19,997,736 |
|
|
$ |
10,772,102 |
|
|